Skip Navigation
  Search Menu
Find an Expert

 

Mark Christopher Markowski, M.D., Ph.D.

Photo of Dr. Mark Christopher Markowski, M.D., Ph.D.

Instructor of Oncology

Male

Expertise: General Internal Medicine, Medical Oncology, Prostate Cancer

Research Interests: Anti-inflammatory agents and cancer incidence; Early phase drug development for prostate cancer

Background

Dr. Mark Markowski is a medical oncologist at the Kimmel Cancer Center at Sibley Memorial Hospital, as well as an instructor in the Department of Oncology at Johns Hopkins University School of Medicine. Dr. Markowski participates in multidisciplinary clinics at Sibley and The Johns Hopkins Hospital, and see patients in the genitourinary clinics of both hospitals. He is board certified in medical oncology and internal medicine by the American Board of Internal Medicine. 

Dr. Markowski treats numerous types of cancers, with a specialty in prostate cancer.

Dr. Markowski earned his medical degree and Ph.D. in tumor biology at Georgetown University School of Medicine. He completed a residency in internal medicine at Columbia University, followed by a medical oncology fellowship at Johns Hopkins Hospital.

Dr. Markowski is a board member and secretary for the Genito-Urinary Multidisciplinary D.C. Regional Oncology Project (GUMDROP).

Dr. Markowski previously served as a research associate at the Lombardi Comprehensive Cancer Center at Georgetown University. His research interests focus on early phase drug development for prostate cancer, and anti-inflammatory agents and cancer incidence. Dr. Markowski is currently conducting research with funding from a Postdoctoral Training Award from the Department of Defense's Prostate Cancer Research Program, and a Young Investigator Award from the Prostate Cancer Foundation, which focuses on new treatment strategies for prostate cancer patients and credentialing these treatments for advancement to clinical trials. 

...read more

Titles

  • Instructor of Oncology

Departments / Divisions

  • Medicine at Sibley Memorial Hospital
  • Oncology - Prostate Cancer and GU

Education

Degrees

  • MD, Georgetown University School of Medicine (2009)

Residencies

  • New York Presbyterian Hospital - Cornell Campus / Internal Medicine (2012)

Fellowships

  • Johns Hopkins University School of Medicine / Medical Oncology (2016)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2012)
  • American Board of Internal Medicine / Medical Oncology (2016)

Research & Publications

Selected Publications

View all on Pubmed

Markowski MC, Imus P, Wright JL, Schottenstein D, Paller CJ. "Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report." Clin Genitourin Cancer. 2017 Oct;15(5):e839-e842. doi: 10.1016/j.clgc.2017.02.001. Epub 2017 Feb 27.

Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. "Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide." Prostate. 2016 Dec;76(16):1484-1490. doi: 10.1002/pros.23232. Epub 2016 Jul 12.

Markowski MC, Carducci MA. "Early use of chemotherapy in metastatic prostate cancer." Cancer Treat Rev. 2017 Apr;55:218-224. doi: 10.1016/j.ctrv.2016.09.017. Epub 2016 Oct 3. Review.

Markowski MC, Wobker SE, Strowd RE 3rd, Antonarakis ES. "Lumbosacral Plexus Involvement as the First Site of Metastatic Recurrence in a Patient With CTNNB1-Mutant Prostate Cancer." Clin Genitourin Cancer. 2016 Aug;14(4):e417-22. doi: 10.1016/j.clgc.2016.02.001. Epub 2016 Feb 23.

Markowski MC, Eisenberger MA, Zahurak M, Epstein JI, Paller CJ. "Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital." Urology. 2015 Sep;86(3):539-43. doi: 10.1016/j.urology.2015.06.011. Epub 2015 Jun 28.

Activities & Honors

Honors

  • Young Investigator Award, Prostate Cancer Foundation
  • Postdoctoral Training Award, Department of Defense, Prostate Cancer Research Program

Memberships

  • Genito-Urinary Multidisciplinary D.C. Regional Oncology Project (GUMDROP)

    Board Member and Secretary

Videos & Media

Recent News Articles and Media Coverage

ASCO 2017: PSA doubling time and proximal PSA value predict metastasis-free survival in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy, UroToday, 2017.

Proximal PSA Predicts Prostate Cancer Metastasis Risk, Renal and Urology News, Sept. 13, 2017.

Is this you? Edit Profile